EP3826662
Aðferð við að nota GIP/GLP1 samörva fyrir sykursýki
Status:
EP einkaleyfi: Endurútgefin þýðing EP einkaleyfisEP appl. date:
22.7.2019EP published:
11.9.2024EP application number:
19749938.7
EP translation filed:
14.10.2024Grant published:
15.11.2024EPO information:
European Patent Register
Max expiry date:
21.7.2039Expiry date:
21.7.2027Next due date:
31.7.2027
Title in English:
METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETESLanguage of the patent:
English
Timeline
Today
22.7.2019EP application
11.9.2024EP Publication
14.10.2024Translation submitted
15.11.2024Registration published
21.7.2027Expires
Owner
Name:
Eli Lilly and CompanyAddress:
Lilly Corporate Center, Indianapolis, IN 46285, US
Inventor
Name:
ALSINA-FERNANDEZ, JorgeAddress:
Indianapolis, Indiana 46206-6288, US
Name:
CABRERA, OverAddress:
Indianapolis, Indiana 46206-6288, US
Name:
COSKUN, TamerAddress:
Indianapolis, Indiana 46206-6288, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862702180 PDate:
23.7.2018Country:
US
Number:
201862730562 PDate:
13.9.2018Country:
US
Number:
201862740640 PDate:
3.10.2018Country:
US
Classification
Categories:
A61K 38/26, A61P 3/10
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 9.7.2025
Expires: 21.7.2026
Payer: Árnason Faktor ehf.
Number: 8
Paid: 24.6.2026
Expires: 21.7.2027
Payer: Anaqua